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Abstract
Cancer metastasis is a frequent manifestation of
malignant melanoma progression. Successful inva-
sion into distant organs by tumor cells must include
attachment to microvessel endothelial cells, and
degradation of basement membranes and extracellular
matrix (ECM). Heparan sulfate proteoglycans (HSPG)
are essential and ubiquitous macromolecules associ-
ated with the cell surface and ECM of a wide range of
cells and tissues. Heparanase (HPSE-1) is an ECM
degradative enzyme, which degrades the heparan
sulfate (HS) chains of HSPG at specific intrachain
sites. To investigate effects of changes in heparanase
gene expression in metastatic melanoma cells, we
constructed adenoviral vectors containing the full-
length human HPSE-1 cDNA in both sense (Ad-S/hep)
and antisense orientations (Ad-AS/hep). We found
increased HPSE-1 expression and activity in melano-
ma cell lines following Ad-S/hep infection by Western
blot analyses and specific HPSE-1 activity assay.
Conversely, HPSE-1 content was significantly in-
hibited following infection with Ad-AS/Hep. Impor-
tantly, HPSE-1 modulation by these adenoviral
constructs correlated with invasive cellular properties
in vitro and in vivo. Our results suggest that HPSE-1
not only contributes to the invasive phenotype of
melanoma cells, but also that the Ad-AS/hep-mediated
inhibition of its enzymatic activity can be efficacious in
the prevention and treatment of melanoma metastasis.
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Introduction
Mechanisms responsible for melanoma progression to
highly aggressive metastatic disease are not fully under-
stood. However, it is known that proteolytic enzymes play
important roles due to their involvement in extracellular matrix
(ECM) disassembly, which allows tumor cells to invade into
distant organs. Heparan sulfate proteoglycans (HSPG) [1]
are now recognized as cell surface/ECM active biologic mod-
ulators [2], and their degradation at the level of heparan
sulfate glycosaminoglycan chains (HS) has significant regula-
tory consequences in cancer metastasis. Elevated levels
of heparanase (HPSE-1) are known to be associated with
brain-metastatic melanoma [3–7]. HPSE-1 is an endo-b-D-
glucuronidase [8] involved in the degradation of cell surface/
ECM HSPG of a wide range of normal and neoplastic tissues
[9–13] and a molecular determinant of metastatic events.
The enzymatic activity of HPSE-1 is characterized by specific
intrachain HS cleavage of glycosidic bonds with a hydrolase
(but not eliminase) type of action, therefore facilitating the
release of several protein modulators of cell function, includ-
ing migration, adhesion, inflammation, angiogenesis, embryo-
genesis, and metastatic invasion [8–17]. Secondly, HPSE-1
levels have been found to be increased in sera and urine of
human patients withmetastatic cancers [8,18]. Thirdly, HPSE-1
activity correlates with the metastatic potential of tumor cells
in animal models, resulting in increased mortality [15]. Finally,
enhanced HPSE-1 mRNA levels correlate with reduced post-
operative survival in cancer patients [10,15].
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HPSE-1 from various mammalian sources has been
cloned as a single gene family [9–12], representing the
dominant HS-degradative enzyme. Importantly, HPSE-1
regulation has been shown to change metastatic properties
of tumors [10,19,20]. For example, an upregulation of the
enzyme has been shown to increase the metastatic proper-
ties of tumor cells [10,19]. Conversely, downregulating
HPSE-1 by antisense strategies [19,20] demonstrated a
reduction in the invasive properties of neoplastic cells.
Evidence has also demonstrated that HPSE-1 is a poten-
tial target for antimetastasis drugs because of its critical roles
in angiogenic and invasive processes: treatment of experi-
mental animals with HPSE-1 inhibitors considerably reduced
the incidence of tumor invasion and angiogenesis in animal
models [16,21]. Extensive available animal and clinical data
suggest that HPSE-1 may play an important role in the
progression of a variety of human tumors. Nevertheless,
the possible role(s) of HPSE-1 in tumor progression at the
molecular and cellular levels is poorly understood.
These observations led us to hypothesize that inhibition of
HPSE-1 expression could inhibit tumor cell invasion by
metastatic melanoma cells. Here we demonstrate that an
adenoviral vector expressing the full-length human hepara-
nase gene in an antisense orientation specifically inhibits
HPSE-1 expression as well as its invasiveness, leading to a
reduction of invasive capabilities by metastatic melanoma
cells in vitro and in vivo. Our results further support the fact
that inhibiting HPSE-1 can change the invasive properties of




HS from bovine kidney was acquired from Sigma Chem-
ical Co. (St. Louis,MO). Dulbecco’smodified Eagle’smedium
(DMEM), Ham’s F-12 nutrient medium, and trypsin–ethyl-
enediaminetetraacetic acid (EDTA) were purchased from
Gibco (Grand Island, New York, NY), and fetal bovine serum
(FBS) was from Hyclone Laboratories (Logan, UT). Human
recombinant HPSE-1 was kindly provided by Dr. Edward
McKenzie [22]. The polyclonal antibodies to human HPSE-
1 were generously provided by Dr. Laurie A. Dempsey
(MayoClinic, Rochester, MN) and Dr. Robert L. Heinrikson
(Pharmacia-Upjohn, Inc., Kalamazoo, MI).
Transwell cell culture chambers were purchased from
Corning Incorporated Life Sciences (Acton, MA), whereas
Matrigel was obtained from BD Biosciences Discovery
Labware (Bedford, MA) and fibronectin was from ICN
Biochemical (Irvine, CA). All other chemicals used were of
reagent-grade or better.
Cells and Tissue Culture Conditions
Early-passage melanoma cells with varying metastatic
abilities, both of murine (B16B15b line [23]) and human origin
(70W line [24,25]) were maintained as monolayer cultures
in a 1:1 (vol/vol) mixture of DMEM/F-12 supplemented with
10% (vol/vol) FBS and 5 mM sodium butyrate (B16B15b)
or 10% (vol/vol) FBS (70W). B16B15b and 70W metastatic
melanoma cells (with the lung being the primary colonization
site) were chosen as a source of HPSE-1 because they
are highly invasive and produce HPSE-1 at elevated levels
versus their respective parental counterparts [3,4]. Cells
were maintained at 37jC in a humidified 5% CO2/95%
air (vol/vol) atmosphere and passaged using 2 mM EDTA
(B16B15b) or trypsin–EDTA (70W) before reaching conflu-
ence. The transformed embryonic kidney cell line 293
was grown in DMEM/F-12 and supplemented with 10%
FBS, penicillin (100 U/ml), and streptomycin (100 mg/ml).
The 293 cells were used for the production of adenoviral
vectors [19].
Construction of Recombinant Adenovirus Containing
the Human Heparanase Gene
An adenovirus expression vector kit (Takara Biomedicals,
Inc., Tokyo, Japan) was used to generate recombinant
adenovirus for the expression of human HPSE-1 gene in
both sense and antisense orientations. Replication-deficient
E1-deleted and E3-deleted recombinant adenovirus sero-
type 5 (Ad5) was used as the viral backbone. Plasmid DNA
containing the cloned HPSE-1 gene and synthetic oligonu-
cleotides Hep-5V (complementary to the 5V end of the gene)
and Hep-3V (complementary to the 3V end of the gene) were
used to produce polymerase chain reaction (PCR) products
encompassing the HPSE-1 sequence (1632 bp). PCR prod-
ucts were treated with T4 DNA polymerase to generate
uniformed blunt ends required for the ligation reaction into
pAxCAwt cosmid provided by the Takara kit. After cloning
the HPSE-1 gene into the cosmid vector, availability of the
recombinant cosmids containing the target gene in sense
(5V–3V under the CAG promoter of the vector) and antisense
(3V–5V) orientations was confirmed by restriction analysis.
Cosmid DNA were produced in large quantities and, after
gradient purification, were used for cotransfection with ade-
novirus genomic DNA–terminal protein complex (DNA–
TPC provided by the kit) into 293 cells. Following the kit
protocol, recombinant adenoviruses expressing human
HPSE-1 in both sense (Ad-S/hep) and antisense (Ad-AS/
hep) orientations were generated. Integrity of these recom-
binant viruses was confirmed by PCR and restriction analy-
sis. The E1-deleted and E3-deleted replication-deficient
adenovirus pAd5-Blue was used as the control vector. Viral
titer was quantified by determination of 50% infectivity on
tissue culture (TCID50) in 293 cells.
Adenoviral Infection
70W and B16B15b cells were plated on 100-mm dishes
(106 cells/dish). Twenty-four hours later, cells were washed
twice with phosphate-buffered saline (PBS) containing
2 mM EDTA, and infected with virus diluted in serum-free
DMEM/F-12. To maximize cell viability and protein expres-
sion, cells were infected with viral vectors at a multiplicity
of infection (MOI) of 30 to 50. Plates were then incu-
bated at 37jC for 1 hour, gently rocking every 10 minutes.
Infection was terminated by adding a culture medium
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containing penicillin (100U/ml) and streptomycin (100 mg/ml).
Cells were then incubated at 37jC for an appropriate
period of time. Immunofluorescent control experiments
were performed to confirm the cell infectivity of our adeno-
viral vectors.
Reverse Transcription (RT) PCR Analysis
Total RNA was isolated from cells using the RNeasy kit
(Qiagen, Inc., Valencia, CA). Briefly, RT was performed at
42jC for 1 hour, and PCR was performed using specific
primers (final volume, 25 ml). The following specific primers
were used: HPSE-1 sense (HPSE-S: 5V-TTC GAT CCC AAG
AAG GAA TCA AC-3V) and HPSE-1 antisense (HPSE-AS:
5V- TAC ATG GCA TCA CTA C-3V); for the sequence just
after the inserted fragment in the vector (Ad5 pax: 5V-ATC
GAT TCT AGA CTA GTT TAA TTA ATT T-3V); control
glyceraldehyde-3-phosphate dehydrogenase, sense (5V-
TGA AGG TCG GAG TCA ACG GAT TTG GT-3V) and
antisense (5V-CAT GTG GGC CAT GAG GTC CAC CAC-
3V). The amplification reaction for HPSE-1–, Ad-S/hep–, and
Ad-AS/hep – specific constructs involved 35 cycles
of denaturation at 95jC for 45 seconds, annealing at
52jC for 1 minute, and 72jC for 1 minute. The amplifi-
cation for GAPDH reaction involved 35 cycles of denatur-
ation at 94jC for 30 seconds and annealing at 68jC for
3 minutes in the GeneAmp PCR system 9700 (Applied
Biosystems, Foster City, CA). PCR products were subse-
quently resolved on 1% agarose gels and visualized by
ethidium bromide staining.
Western Blot Analysis
Cells were plated (106 cells/plate) on 100-mm dishes and
allowed to attach and grow for 24 hours. Cells were subse-
quently infected with Ad-S/hep, Ad-AS/hep, or pAd5-Blue
control vector and incubated for 36 to 48 hours. They were
then released and centrifuged (300 rpm for 5 minutes) and
resuspended in lysis buffer [TBS (pH 7.4) containing Triton-X
100 (0.5%), leupeptin (10 mg/ml), pepstatin (10 mg/ml), and
PMSF (0.2 mM)] at a density of 108 cells/ml. Cells were
subsequently vortexed and kept on ice for 10 minutes
followed by centrifugation for 10 minutes at 13,000 rpm at
4jC. The supernatant was collected and protein concentra-
tion was determined by bicinchoninic acid (BCA) assay.
Protein samples (60–90 mg) were then incubated at 100jC
for 10 minutes with Laemmli sample buffer [26] and sepa-
rated on 10% Criterion gels (Tris–HCl; Bio-Rad Laboratories
Inc., Hercules, CA). Gels were transferred to a PVDF mem-
brane (Pierce Endogen, Inc., Rockford, IL) and incubated
overnight (18 hours) in a blocking reagent [3% (wt/vol) nonfat
dry milk, 0.5% (wt/vol) bovine serum albumin (BSA), 0.3%
(vol/vol) Tween-20 in PBS, pH 7.5]. HPSE-1 protein was
labeled using anti –HPSE-1 polyclonal antibody (PAb;
1:5000 dilution; Mayo Clinic) in 3% (wt/vol) nonfat dry milk
and 0.5% (wt/vol) BSA, washed for 1 hour with six to eight
changes of 0.5% IGE-PAL (CA-630; Sigma Chemical Co.) in
Tris buffer (20 mM Tris, 150 mM NaCl, pH 7.4), and then
incubated with horseradish peroxidase (HRP)–antirabbit
immunoglobulin G (IgG; 1:5000 dilution; Accurate Scientific,
Westbury, NY). It was subsequently washed and developed
using the Supersignal west femto maximum sensitivity sub-
strate (Pierce Endogen, Inc.). Dual-Color Precision Plus
Protein Standards (Bio-Rad Laboratories Inc.) were used
as molecular weight markers. Labeling was detected and
quantified using a Versadoc imaging system (Quantity One;
Bio-Rad Laboratories Inc.).
HPSE-1 Activity Assays
HPSE-1 activity was determined by degradation of FITC-
labeled heparan sulfate (FITC-HS) using high-speed gel
permeation column chromatography (HPLC) as previously
described [9,27]. Briefly, cell lysates (80 mg cell lysate/mg of
HS) were prepared as described above and incubated with
FITC-HS at 37jC for 18 hours in 100 ml of sodium acetate
(100 mM, pH 4.2). Reaction was terminated by heating
samples at 100jC for 15 minutes. HS products yielded by
HPSE-1 reaction were analyzed by size exclusion chroma-
tography performed on a HP1090 liquid chromatograph with
a photodiode array detector (Agilent Technologies, Inc.,
Wilmington, DE) and a HP1046 programmable fluorescence
detector (Agilent Technologies, Inc.). Samples (25 ml)
were injected on a TSK-GEL 3000SWXL column (5 mm,
7.8 mm  30 cm) with a TSK-GEL SWXL guard column
(5 mm, 6.0 mm  4.0 cm) from Tosoh Bioscience (Mont-
gomeryville, PA) at ambient temperature (25jC). Samples
were isocratically eluted using Tris–HCl (25 mM), NaCl
(150 mM), pH 7.5, at a flow rate of 0.5 ml/min with a sample
splitter placed between the column and detectors to maintain
a column pressure of less than 70 bar. Fluorescence was
monitored with excitation at 490 nm and emission at 520 nm,
then data were processed and peaks were integrated using
HP ChemStation software (Agilent Technologies, Inc.).
HPSE-1 activity was determined by measuring the decrease
in fluorescence intensity in the first half area of the intact
FITC-HS peak chromatogram. The retention times were
calculated from the highest peak of the chromatograms.
Alternatively, a commercial heparan-degrading enzyme
assay kit (Takara Mirus Biomedical, Inc., Madison, WI) was
used to determine HPSE-1 activity in melanoma cells [27].
Indicated amounts of cell lysate were incubated with biotiny-
lated HS at 37jC for 45 minutes and HPSE-1 activity was
determined by an enzyme-linked immunosorbent assay
(ELISA)–type assay. Color was developed using the sub-
strate supplied in the kit and plates were read at 450 nm
using amicroplate reader (EL 808; Bio-Tek Instruments, Inc.,
Winooski, VT).
Chemoinvasion Assays
Invasive properties of melanoma cells were assayed by
Boyden’s chambers as previously described [3]. Briefly, cell
invasion was assayed using Transwell cell culture chambers
(12 mm pore size, 12 mm diameter) coated with Matrigel
[diluted as 38 mg/ml in cold DMEM/F-12 with penicillin/
streptomycin (P/S), 100 ml final coating volume], which was
applied to the upper filter surface and allowed to dry before
use. Cells were plated on day 1 and, after 24 hours, were
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infected with Ad-S/hep, Ad-AS/hep, or the control vector
pAd5-Blue as described above. Twenty-four hours later,
cells were released from the culture plate and added to the
upper chamber of invasion plates (1.2  105 cells/chamber)
in serum-free DMEM/F-12. Lower chambers contained
n-formyl-L-methyl-L-leucine-L-phenylalanine (5 nM) in
DMEM/F-12 with 10% (vol/vol) FBS and fibronectin (1 mg/ml)
as chemoattractants. Cells were incubated in invasive cham-
bers for 48 to 72 hours at 37jC in a humidified 5% CO2/95%
air (vol/vol) atmosphere. At the end of the experiment,
Transwell membranes were lifted from the wells carefully
without touching the bottom. Noninvasive cells were wiped
from the upper chamber with a cotton swab and invasive
cells were visualized with Diff-Quick Stain Kit (IMEB, Inc.,
San Marcos, CA) according to the manufacturer’s instruc-
tions. Briefly, membranes were dipped in solution A (meth-
anol) for 2 minutes and allowed to air dry. Membranes were
then transferred in solution B (Eosin), dipped 25 times,
transferred in solution C (Azure), and then dipped 25 more
times. After rinsing with deionized water, membranes were
inverted and allowed to dry. By using this kit, the nuclei of
cells are stained blue and cell cytoplasm is stained pink. The
number of invasive cells was obtained by counting the nuclei
under the microscope.
In Vivo Tumorigenic Assays
Human malignant melanoma 70W cells were infected
with Ad-S/hep, Ad-AS/hep, and control pAd5-Blue at an
MOI of 50. Cells were harvested 36 hours after infection,
and resuspended in DMEM/F-12 at a density of 5.0  106
cells/ml. Six-week–old female athymic nu/nu mice were
injected intravenously (tail vein) with 200 ml of cell suspen-
sion (106 cells) through a 27-gauge needle. Mice were
euthanized and examined for tumor formation as previously
described [25]. Metastatic behavior per animal group (num-
ber of lung nodules and lungs wet weight; N = 15) was then
determined. Additionally, lung tumor tissues were saved in
formalin, and random samples were taken and stained with
hematoxylin and eosin and analyzed under microscopy.
Immunohistochemical Analysis
Immunohistochemical staining was performed using a
Vectastain ABC kit (Vector Laboratories, Inc., Burlingame,
CA) according to the instructions provided by the manufac-
turer. Formalin-fixed, paraffin-embedded tissue sections
from in vivo tumorigenic assays were mounted on silanized
slides and deparaffinized. Endogenous peroxidase was
blocked by incubating the sections in 3.0% H2O2 without
pretreatment. After the blocking of nonspecific reactivity with
rabbit serum for 30 minutes at room temperature (25jC),
sections were incubated at 4jC for 60 minutes with the
antihuman HPSE-1 rabbit PAb raised against human
HPSE-1 (Pharmacia-Upjohn, Inc.). Following rinsing, slides
were incubated with biotinylated antirabbit IgG and then with
Vectastain ABC reagent. Peroxidase activity was deter-
mined using nova red and counterstained with hematoxylin.
As a negative control, sections were subjected to normal
serum blocking with omission of the primary antibody.
Results
Detection of HPSE-1 mRNA Expression in Sense
or Antisense Orientation
To examine the significance of human HPSE-1 in meta-
static melanoma cell invasion, we constructed replication-
defective recombinant adenoviruses expressing sense
and antisense RNA to a full-length human HPSE-1 se-
quence, Ad-S/hep, and Ad-AS/hep, respectively. Both sense
and antisense transcripts of HPSE-1 could be detected
when HPSE-S and HPSE-AS primers were used in 70W
cells, but not in the B16B15b cells because primers chosen
against human heparanase did not amplify the murine hep-
aranase. Strand-specific primer pairs (HPSE-S and Ad5pax,
or HPSE-AS and Ad5pax) detected the expression of the
sense and antisense constructs in B16B15b and 70W mel-
anoma cells with Ad-S/Hep or Ad-AS/hep treatment, respec-
tively (Figure 1).
Modulation of HPSE-1 Protein Levels Following Ad-S/Ad-AS/
hep Infection in Melanoma Cells
Western blot analyses were performed to examine the
effects of Ad-S/hep and Ad-AS/hep infection on HPSE-1
protein levels in B16B15b and 70W cells (Figure 2). Because
HPSE-1 is a low-abundance protein, 60 to 90 mg of total cell
lysate had to be electrophoresed in order to detect adequate
HPSE-1 levels. HPSE-1 protein expression increased with
Ad-S/hep and decreased with Ad-AS/hep–treated mela-
noma cells compared to treatment with control vector pAd5-
Blue in both B16B15b (Figure 2A) and 70W (Figure 2B) cells.
HPSE-1 is a heterodimer consisting of a 50-kDa and a 8-kDa
band processed from a proenzyme precursor (65 kDa) by
proteolytic cleavage, and presence of the 8-kDa band is
essential for its enzymatic activity [11,18,28]. We detected
the active form of HPSE-1 in the cells; however, it migrated
Figure 1. Expression of human heparanase sense and antisense transcripts
in melanoma cells. B16B15b and 70W cell lines were infected with pAd5-Blue
(lanes 1 and 4), Ad-S/hep (lanes 2 and 5), or Ad-AS/hep vector (lanes 3 and
6) and subjected to RT-PCR analysis 36 hours after infection. Two primer
pairs, HPSE-S/Ad5 pax and HPSE-AS/Ad5pax, were designed to, respec-
tively, detect sense and antisense transcripts of the human heparanase gene.
Both sense and antisense transcripts of HPSE-1 could be detected when
HPSE-S and HPSE-AS primers were used in 70W cells, but not in the
B16B15b cells because the primers chosen against human heparanase gene
did not amplify murine heparanase. Primers and predicted products are
indicated at the side of panel.
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slightly slower than its predicted molecular weight (50 kDa).
This is consistent with the recent findings by Simizu et al. [29],
and possibly due to posttranslational modification in the
glycosylation of the enzyme. We also detected a weak band
representing the 65-kDa inactive precursor in B16B15b cells.
Furthermore, we found a two-fold increase in HPSE-1 protein
level using the Ad-S/hep vector and a 30% decrease with the
Ad-AS/hep in the B16B15b cell line (Figure 2A). In 70W cells,
we observed a 30% increase or decrease in HPSE-1 protein
by densitometric analysis following Ad-S/hep or Ad-AS/hep
treatment, respectively (Figure 2B).
HPSE-1 Activity Is Upregulated in Ad-S/hep–Treated
Melanoma Cells
We used a specific HPSE-1 activity assay on fluorescein
isothiocyanate (FITC)– labeled HS in 70W cells. This assay
detects HPLC profile shifts based on the size of HS frag-
ments [9,27]. Because HPSE-1 cleaves the HS into discrete
fragments, we detected a profile shift when compared to
FITC-HS alone, which was used as negative control [9,27]
(data not shown). We observed a decrease in fragment size
in Ad-S/hep–treated 70W cells compared to mock-infected
cells. We did not observe a significant difference between
Ad-AS/hep– andmock-treated cells because this represents
a small shift compared to the total profile area (Figure 3A).
However, we observed a significant difference in their re-
spective HPLC retention times, which detect changes in the
size of predominant HS fragments (P = .02). This analysis is
more sensitive to small changes in HS fragment size and
showed less activity with Ad-AS/hep–treated cell lysates
(Figure 3B). The Ad-S/hep–treated cell lysates showed a
higher retention time compared to Ad-AS/hep or mock
treatment, suggesting that increased digestion of HS
resulted from an augmented HPSE-1 activity following Ad-S/
hep treatment in the 70W cell line. We also performed the
ELISA-type assay and found similar changes of HPSE-1
activity in response to pAd5-Blue, Ad-S/hep, or Ad-AS/hep
treatments (Table 1).
Secondly, we measured HPSE-1 activity in B16B15b and
70W cells coinfected with Ad-S/hep and Ad-AS/hep, or
pAd5-Blue vectors using biotinylated HS and an ELISA kit.
Figure 2.Western blot analysis in melanoma cells for HPSE-1 protein expression. Cells (B16B15b and 70W) were infected with pAd5-Blue (lanes 1 and 4), Ad-S/
hep (lanes 2 and 5), or Ad-AS/hep (lanes 3 and 6) (see Experimental Procedures section) and analyzed for HPSE-1 expression after 48 hours. Equal amounts
(60–90 g) of protein were loaded on gels and HPSE-1 protein levels were detected by a rabbit polyclonal antibody and HRP–antirabbit IgG followed by use of the
Supersignal west femto maximum sensitivity substrate. Bands were visualized on a Versadoc imaging system. Quantification was performed using Quantity One
software program (Bio-Rad Laboratories Inc.). (A) Murine B16B15b. (B) Human 70W.
Figure 3. HPSE-1 activity increases with Ad-S/hep treatment in 70W cells
compared to mock-treated cells. Cells were infected with Ad-S/hep, Ad-AS/
hep, or none, and analyzed for HPSE-1 activity after 48 hours. Equal
amounts (100 g) of cell lysates were incubated with FITC-HS for 18 hours
(see Experimental Procedures section) and run on HPLC to analyze HPSE-1
activity. (A) Percentage of HS digested with different treatments. (B)
Retention times calculated with different treatments. Bars represent the
mean with standard deviation of triplicate determinations.
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We detected a dose-dependent inhibition of HPSE-1 activity
with a higher dose of Ad-AS/hep vector (Table 2).
Next, we used suramin, an HPSE-1 antagonist, to inhibit
the activity of Ad-S/hep– infected cells (Figure 4). This
suggests that: 1) increased activity (Figure 4A) and retention
time (Figure 4B) in the assay are due to an upregulation of
HPSE-1 in the Ad-S/hep–infected cells; and 2) this activity
can be further modulated by suramin (500 mM) as an HPSE-1
inhibitor (Figure 4).
Inhibition of HPSE-1–Induced Invasion by Ad-AS/hep
Infection of Melanoma Cells
To investigate HPSE-1 mechanisms in metastatic cell
invasion, chemoinvasion assays were performed using
Matrigel-coated Transwell chamber systems. B16B15b and
70W cells, when infected with Ad-S/hep, possessed aug-
mented invasive properties compared with pAd5-Blue–
infected cells, whereas Ad-AS/hep–treated cells showed a
significant inhibition of invasion (Figure 5). These results
suggest that the antisense adenoviral construct selectively
inhibited HPSE-1–induced invasive properties in B16B15b
and 70W cells.
Inhibition of Tumor Formation with Ad-AS/hep–Treated
70W Cells
To evaluate HPSE-1 mechanism in metastatic cell inva-
sion, human malignant melanoma 70W cells were infected
with Ad-S/hep, Ad-AS/hep, or pAd5-Blue vectors and
injected in 6-week–old female athymic nude (nu/nu) mice.
Mice injected with pAd5-Blue– and Ad-S/hep–treated 70W
cells developed tumors, but none of the Ad-AS/hep–treated
cells was capable of extensive tumor formation (Figure 6,
Table 3). During quantitation of tumor formation, we found
microscopic tumors in one of the mice treated with Ad-AS/
hep, suggesting that the antisense adenoviral construct
selectively inhibited HPSE-1– induced invasive properties
in 70W cells. Because control cells already expressed rela-
tively high levels of HPSE-1, we were unable to see a
significant difference between our control and Ad-S/hep
groups; however, we found a significant difference between
the control and Ad-AS/hep groups. Furthermore, formalin-
fixed tissues from each group were analyzed for immuno-
histochemistry (Figure 7): lung tumor tissue from the Ad-S/
hep group expressed HPSE-1 more consistently and with an
increased immunohistochemical intensity than in the control
group. HPSE-1 staining was also observed in the Ad-AS/hep
group but was mainly due to the presence of the enzyme in
the endothelium [30] and macrophages [13] of lung tissues
(Figure 7).
Discussion
Invasion and metastasis are characteristic features of ma-
lignant tumors and are among the greatest impediments to
curing cancer. Inhibition of tumor invasion is an attractive
approach for the treatment of highly malignant tumors
[31,32]. Substantial evidence accumulated over the last
three decades indicates that HSPG act to inhibit invasion
Table 1. Modulation of HPSE-1 Activity with Ad-S/hep or Ad-AS/hep
Treatment.
Treatment (MOI 50) A450 (nm)*
Pad5-Blue 0.65 ± 0.05
Ad-S/hep 0.21 ± 0.03
Ad-AS/hep 0.73 ± 0.06
*The higher the OD value, the lower the HPSE-1 activity. The A450 starting
point of no enzyme degradation was 0.79.
Table 2. HPSE-1 Activity Decreases with Ad-AS/hep Treatment in a Dose-
Dependent Manner.
Cell Line Treatment (MOI) A450 (nm)*
pAd5-Blue Ad-S/hep Ad-AS/hep
B16B15b – – – 1.1 ± 0.19
125 – – 1.0 ± 0.14
100 25 – 0.87 ± 0.01
50 25 50 0.92 ± 0.03
– 25 100 1.2 ± 0.10
70W – – – 0.90 ± 0.33
125 – – 0.83 ± 0.04
100 25 – 0.59 ± 0.01
50 25 50 0.72 ± 0.02
– 25 100 0.87 ± 0.16
*The higher the OD value, the lower is the HPSE-1 activity. The A450 starting
point of no enzyme degradation was 1.7.
Figure 4. HPSE-1 activity is inhibited by suramin in Ad-S/hep– treated 70W
cells. Cells were infected with Ad-S/hep or pAd5-Blue as control and
analyzed for HPSE-1 activity after 48 hours. Equal amounts (80 g of protein/
g of HS) of cell lysates were incubated with FITC-HS for 18 hours (see
Experimental Procedures section) with or without suramin (500 M) and run
on HPLC to analyze HPSE-1 activity. (A) The percentage of HS digested with
different treatments. (B) Retention times calculated with different treatments.
Bars represent the mean with standard deviation of triplicate determinations.
258 Antisense-Mediated Heparanase Suppression of Melanoma Cell Invasion Roy et al.
Neoplasia . Vol. 7, No. 3, 2005
by promoting tight cell –cell and cell –ECM interactions
[1,33,34]. Degradation of HS weakens cell–cell and cell–
matrix adhesion in melanoma and other tumor cells [35–37].
HSPG can also act both as reservoirs of growth factors
[15,38] and as coreceptors for ligand binding and subse-
quent intracellular signaling. These heparin-binding factors
are involved in growth, invasion, angiogenesis, and tumor
progression [1,15,33]. HS-degradative enzymes, such as
heparitinases, heparinases from Flavobacterium heparinum,
or endoglucosaminidases, cleave HS to disaccharides and
tetrasaccharides, which are too short for growth factor and
ECM ligand binding [39–41]. However, HPSE-1 is an endo-
b-D-glucuronidase that cleaves HS at specific intrachain
sites, resulting in fragments of appreciable size (10–20 sugar
units) [8,15,30,42]. This confirms the notion that HPSE-1,
in degrading HSPG and releasing HS-bound angiogenic/
growth factors, may aid the modulation of growth factor ac-
tivities in metastasis [27,43]. Thus, HPSE-1 is an attractive
target for the development of novel antimetastatic drugs
because of the considerable evidence implicating this en-
zyme in tumor cell invasion [15].
In the present study, we have demonstrated that over-
expression of human HPSE-1 enhanced tumor cell invasive-
ness in vitro and in vivo, and that this invasive ability was
significantly reduced by inhibiting HPSE-1 expression using
an adenovirus-mediated antisense gene delivery strategy.
HPSE-1 expression, as well as its biologic activity, were
enhanced in metastatic melanoma cell lines following Ad-S/
hep treatment. Conversely, treatment with Ad-AS/hep
resulted in decreased HPSE-1 expression as well as cell
invasiveness in vitro and in vivo. For example, in our experi-
ments designed to analyze the effects of Ad-S/hep, we found
that there was an upregulation of protein expression in both
B16B15b and 70W melanoma cell lines. Conversely, we
observed the opposite using Ad-AS/hep (Figure 2). The
reduction in HPSE-1 protein level was consistent over mul-
tiple experiments. The inability to completely inhibit HPSE-1
protein expression was possibly due to slow protein turnover
rate. However, the reduction results in significant biologic
effects in in vitro invasion assays or in in vivo tumorigenic
assays, despite this small change in the protein level.
HPSE-1 activity was inhibited in a dose-dependent man-
ner when cells were coinfected with Ad-S/hep and different
doses of Ad-AS/hep (Table 2). Furthermore, we detected
an increase in HPSE-1 activity with Ad-S/hep infection
(Figure 3, Table 1). There was a small reduction of activity
with Ad-AS/hep treatment compared to mock-treated cells
(Figure 3A), which significantly decreased when HPLC
retention times were calculated from these experiments
(P = .02) (Figure 3B).
Figure 6. Ad-AS/hep treatment inhibits tumor formation in athymic nude (nu/nu) mice. Human malignant melanoma 70W cells were infected with pAd5-Blue control
vector (A), Ad-S/hep (B), or Ad-AS/hep (C) and were injected intravenously in 6-week–old female athymic nu/nu mice. At the end of the experimental period, mice
were euthanized and examined for tumor formation, as described [25]. Quantification of lung tumor formation and statistical analyses were performed on a number
of experimental animals and shown in Table 3.
Figure 5. Ad-AS/hep treatment inhibits HPSE-1–mediated invasion of
melanoma cells. Metastatic melanoma cells (B16B15b and 70W) infected
with pAd5-Blue, Ad-S/hep, or Ad-AS/hep were placed in invasion chambers
(12 m diameter pore size) for 72 hours at 37jC in a humidified 5% CO2/95%
air (vol/vol) atmosphere. Noninvasive cells were wiped from the upper
chamber with a cotton swab and invasive cells were detected with the Diff-
Quick Stain Kit. Bars represent the mean with standard deviation of triplicate
determinations (*P < .01, **P < .1). Student’s t test was used as statistical
method.
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Wewere also able to inhibit the increased activity of Ad-S/
hep with suramin, a known HPSE-1 inhibitor, therefore re-
lating this augmented cell invasiveness to HPSE-1 (Figure 4).
The poor sensitivity of HPSE-1 activity assays may reflect a
lack of sensitivity at low HPSE-1 levels. Alternatively, dif-
ferences between HPSE-1 activity and biologic assays can
be due to lysis of the cells (HPSE-1 activity assays) versus
using intact cells in in vitro (invasion assays) and in vivo
(tumorigenic assays) analyses. In fact, we observed both a
significant biologic effect in chemoinvasion assays and a
reduction in both B16B15b and 70W cell-invasive properties
(Figure 5). Of equal importance, mice injected with pAd5-
Blue– and Ad-S/hep–treated 70W cells showed extensive
tumor formation, whereas none of the mice injected with
Ad-AS/hep–treated 70W cells presented any evidence of
macroscopic malignancy (Figure 6, Table 3). Because con-
trol cells already expressed high levels of HPSE-1, we were
unable to detect a significant difference between control and
Ad-S/hep groups; however, this was found between the
control and Ad-AS/hep groups (P = .04). Secondly, immuno-
histochemical analyses on the animal tissue from each group
revealed more consistent and intense HPSE-1 staining in
Ad-S/hep–infected cells (Figure 7, C and D) compared to
using pAd5-Blue (Figure 7, A and B) or Ad-AS/hep vectors
(Figure 7, E and F ). These findings indicate that even a
small reduction in HPSE-1 activity can lead to a great
difference in its biologic function and may also suggest that
the antisense-mediated gene delivery strategy can be a
very effective way in preventing tumor formation and its
metastatic potential.
Many chemotherapeutic agents are available to target
HPSE-1 to suppress metastasis [44–47]. However, these
agents have their limitations in affecting malignant cells as
well as normal cells, thus affecting the normal growth and
functions of vital organs. Secondly, delivering these agents
to specific sites can be difficult. Finally, interactions be-
tweenthe antimetastatic agents and biologic molecules like
HSPG can interfere with normal biologic processes. Ac-
cordingly, to specifically inhibit themetastatic potential, which
is a frequent malignant phenotype of many tumor types, a
more specific therapeutic approach, such as the antisense-
mediated RNA expression, needs to be considered. Anti-
sense RNA can bind to the mRNA expressing the gene of
interest and can block protein expression by the target cells.
Several groups have reported that tumor cells transfected
with HPSE-1 cDNA acquire a highly metastatic phenotype
in vivo [10] (reviewed in Ref. [15]). Conversely, inhibition of
HPSE-1 by means of antisense strategy, antimetastatic
drugs, or gene silencing has resulted in decreased invasive-
ness in vitro [20] and in vivo [19,48]. However, in other
antisense animal models, tumor cells treated with viral
vectors were directly injected into the thoracic cavity [19],
which bypasses several steps in the metastatic process that
includes adhesion to endothelium and invasion [8–17]. A
recent report of HPSE-1 inhibition by siRNA strategy also
demonstrated reduced tumor load and increased survival in
animals [48]. Consistent with these findings, we have ob-
served a significant inhibition of tumor formation in in vivo
Table 3. Ad-AS/hep Treatment Inhibits Tumor Formation in Nude (nu/nu)
Mice.
Treatment Number of Lung Tumor Nodules Lung Weight
(mg, mean ± SD)
Median Range
pAd5-Blue 16 0–32* 571 ± 154
Ad-S/hep 12 0–44y 453 ± 210
Ad-AS/hep 0 0–4z 366 ± 75
*Eighty percent of mice had lung tumors.
yEighty percent of mice had lung tumors.
zTwenty percent of mice had lung tumors (P = .04). Student’s t test was used
as statistical method.
Figure 7. Ad-S/hep/Ad-AS/hep–mediated HPSE-1 expression in nude (nu/nu)
mice. Animals were injected with pAd5-Blue– , Ad-S/hep– , or Ad-AS/hep–
infected 70W cells and formalin-fixed lung tumor tissues were analyzed by
immunohistochemistry. Intense staining of HPSE-1 was found in lung tissues
of animals treated with Ad-S/hep– infected 70W cells (C and D) compared to
pAd5-Blue (A and B) or Ad-AS/hep (E and F) treatment. HPSE-1 staining
observed in the Ad-AS/hep is due to the presence of the enzyme in the
endothelium [30] and macrophages [13] in lung tissues. Digital images
were produced on an Axioplan microscope with advanced spot imaging
program at 10 (A, C, and E) and 40 (B, D, and F) objectives using
identical conditions for all photographs and antibodies used; 40 objectives
show the different intensities of HPSE-1 staining by various treatments.
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experiments where HPSE-1 – expressing 70W cells
were infected with Ad-AS/hep and subsequently injected in
athymic nu/nu mice (Figure 6, Table 3). This suggests that
Ad-AS/hep has the potential to suppress the metastatic
phenotype of highly invasive tumor cells. Thus, approaches
that selectively block the expression of molecules implicated
in cellular invasion may be clinically more efficacious in
preventing tumor cell dissemination than the ones used to
induce tumor cell apoptosis.
The metastatic phenotype is considered decisive for
tumor progression and several key molecules involved in
these complex biologic events are potential candidates for
therapeutic intervention. HPSE-1 should be considered one
of these.
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